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Childhood osteoporosis can be treated with intravenous
bisphosphonates in order to improve bone mass and
density. The aims of this study were to evaluatethe
safety and efficacy of six-monthly zoledronic acid (ZA)
in children with osteoporosis.
A retrospective cohort study of 27 patients (16 males
and 11 females) weretreated with six-monthly ZA
(0.05mg/kg/dose) for a minimum of one year.17 patients
were immobile, 4 had steroid-induced osteoporosis, 2
had osteogenesis imperfecta and 4 had other diagnoses.
16/27 (59%) had long bone fractures and 12/27 (44.4%)
had vertebral wedging at baseline. Mineral homeostasis,
bone mineral density by DXA and vertebral morphome-
try were evaluated at baseline and 1year.
The median age at commencement of treatment was
12.3 years (range 8-15.8). Following the first infusion, 2/
27 (7%) and 1/27 (4%) developed asymptomatic hypo-
calcemia at 48 hours and 72 hours, respectively.A fever
above 38°C developed in 14/27 (52%), generalised
aches/pains in 13/27 (48%) and nausea in 6/27 (22%).
At 1year there was a significant reduction in bone turn-
over and improvement in bone mineral density (BMD)
(see Table 1). Patients with vertebral wedging at base-
line showed significant improvement in anterior, middle
and posterior vertebral height ratios at 1year. Only one
patient fractured after starting ZA. There was normal
growth.
Six monthly ZA was associated with an acute phase reac-
tion to the first dose and improvement in BMD, reduction
in bone turnover and improved vertebral shape at 1 year.
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Table 1 Mineral homeostasis and DXA data at baseline
and 1 year
Baseline 1 year
Calcium (mmol/L) 2.38 (2.35-2.44) 2.36 (2.28-2.42)
Alkaline phosphatase (U/L) 188 (143-271) 148.5 (127.25-
205.5)*
Osteocalcin (nmol/L) 7.9 (4.35-11.35) 2.5 (1.1-3.95)*
25-OH-VitD (nmol/L) 75 (67-94) 76 (57.5-86)
Parathyroid hormone (pmol/L) 3.5 (2.3-4.1) 3.7 (2.9-5.4)
Total body aerial BMD Z-score -0.56 (-1.7 to
0.35)
-0.03 ( -1.13 to
0.86)*










Values represent median (interquartile range), asterisk represents p<0.05
compared to baseline
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